Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Feb 2023
Online dating has revolutionized dating by creating more opportunities to meet partners than ever before.
Read Full NewsA trial evaluates whether very early FDG PET-guided treatment adaptation after one cycle of brentuximab vedotin-based chemotherapy improves outcomes in Hodgkin lymphoma.
Researchers report that digital monitoring tools may improve symptom tracking, but nurses face added demands linked to alert verification and patient support.
Triple-negative breast cancer patients with residual disease after neoadjuvant chemotherapy do not gain a survival benefit from adding atezolizumab to adjuvant capecitabine, shows trial.
Patients treated with datopotamab deruxtecan reported longer preservation of quality of life and physical functioning vs chemotherapy in metastatic TNBC.
The Oncologic Drugs Advisory Committee backed the prostate cancer drug but rejected a novel approach for breast cancer, highlighting challenges in defining clinical meaningfulness.
A phase 3 trial evaluates the efficacy and safety of nilotinib with pegylated interferon alfa-2a in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
Amid a de-escalation trend in breast cancer treatment, less than one third of patients with inflammatory breast cancer receive guideline-endorsed trimodal therapy, despite survival benefits.
1.
FDA Approves Hemophilia B Second Gene Therapy.
2.
Dasatinib Fails to Improve Outcomes in CBF-AML
3.
Effective Intralesional Melanoma Therapy May Involve Systemic Effects.
4.
A single bout of exercise gives results that could help cancer patients
5.
ASTRO Guideline Addresses Specifics of HPV-Associated Oropharyngeal Cancer
1.
Understanding Pancreatic Cancer: Symptoms, Causes and Risk Factors
2.
AI in Cancer Care: Transforming Research & Treatment with Deep Learning Technologies
3.
A Comprehensive Guide To Understanding Plasma Osmolality
4.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
5.
Dexamethasone and Life Expectancy After Pediatric Stem Cell Transplant
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
2.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part I
4.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
5.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge